The US FDA approved Sage Therapeutics Inc.'s Zulresso (brexanolone) on March 19 as the first agency-endorsed treatment for postpartum depression (PPD). It's also Sage's first approved product, helping the company establish a commercial organization as it completes Phase III development for the more broadly applicable postpartum and major depression candidate SAGE-217.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?